Loading
Health App Recommendation Tool (HART) / Alzheimers Disease Related Dementias · Interventional Study
ClinicalTrials.gov · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a planned, uncontrolled feasibility study of a health app recommendation tool for caregivers of people with Alzheimer's disease and related dementias. No results are reported. The study aims to assess acceptability and usability over a 4-week period using standardized quality-of-life and burden scales; however, the absence of a control group and small planned sample limit the ability to draw conclusions about effectiveness.
Interventional, Single Group, Open label, Supportive Care purpose. Alzheimers Disease Related Dementias; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: HART Use. n = 15. 1 site: United States.
This is a registry record for a planned, uncontrolled feasibility study of a health app recommendation tool for caregivers of people with Alzheimer's disease and related dementias. No results are reported. The study aims to assess acceptability and usability over a 4-week period using standardized quality-of-life and burden scales; however, the absence of a control group and small planned sample limit the ability to draw conclusions about effectiveness.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should note that this is a feasibility study designed to gather user feedback on a novel recommendation tool, not yet evidence of clinical benefit. Results when reported may inform whether HART warrants larger, controlled evaluation.
This is a small, single-centre, uncontrolled feasibility study of a novel digital tool in an understudied population, designed to assess acceptability and usability rather than efficacy.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should note that this is a feasibility study designed to gather user feedback on a novel recommendation tool, not yet evidence of clinical benefit. Results when reported may inform whether HART warrants larger, controlled evaluation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07216716). This is a study registration, not published results. Lead sponsor: University of Pittsburgh. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 15 participants (ESTIMATED). Conditions: Alzheimers Disease Related Dementias. Interventions: OTHER: Health App Recommendation Tool (HART). Primary outcome measures: World Health Organization Quality of Life (WHOQOL-BREF) , Baseline and 4 week follow-up; 36-Item Short Form Health Survey (SF-36) , Baseline and 4 week follow-up; Patient Health Questionnaire-4 (PHQ-4) , Baseline and 4 week follow-up; Zarit Burden Interview (ZBI) , Baseline and 4 week follow-up; Global Fatigue Index (GFI) , Baseline and 4 week follow-up. Brief summary: This study aims to assess the effectiveness of the Health App Recommendation Tool (HART), an evidence-based tool that evaluates app features and matches them to the needs, abilities, and preferences of individuals with Alzheimer's disease and related dementias (ADRD) or their caregivers. This novel tool is not an app in and of itself, but rather an assessment tool used to determine how well suited a given app is for a member of the ADRD or caregiver population. Specifically, the objective of this research is to assess the acceptability of the current HART design among target end-users in their individual contexts. The overarching goal of this project is to connect those in the ADRD community with available, usable, and effective digital tools to promote the highest possible level of health and wellness in community settings. To achieve this goal, the study will recruit 15 family caregivers living with their loved ones with ADRD, who will trial HART and provide feedback. Participation will include two data collection sessions (pre-intervention and post-intervention) within a four-week trial period. Participants will be asked to complete the HART, explore the recommended apps, and provide feedback on HART's usability through several brief surveys.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.